ValiRx Plc (LON:VAL)‘s stock had its “speculative buy” rating reissued by investment analysts at Beaufort Securities in a note issued to investors on Friday. They currently have a GBX 6.50 ($0.09) price objective on the stock.

Shares of ValiRx Plc (LON:VAL) traded down 6.98% during trading on Friday, reaching GBX 1.00. The company’s stock had a trading volume of 1,724,105 shares. The company’s market capitalization is GBX 1.44 million. ValiRx Plc has a one year low of GBX 0.95 and a one year high of GBX 7.88. The firm’s 50-day moving average price is GBX 1.37 and its 200-day moving average price is GBX 1.95.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at

ValiRx Plc Company Profile

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with's FREE daily email newsletter.